Hutchison China Meditech - HCM Stream Log

Live Discuss Polls Ratings
View
Page
10:13 20/06/2016

"Chi-Med has announced the initiation of a Phase II expansion of the ongoing TATTON trial (NCT02143466) to evaluate the selective c-Met inhibitor savolitinib (AZD6094) in EGFR mutant non-small cell lung cancer (NSCLC) patients. The announced initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med." Panmure note out this morning on Research Tree

10:13 20/06/2016

Welcome to the new Hutchison China Meditech stream forum! Messages posted in the Hutchison China Meditech stream will be logged here for posterity.

Page